Recent News
Read ArticleA Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
Pain Relief in RA: JAK Better than TNF Inhibitors?
MedPage Today
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
Read Article
US health expenditures grew from $4.1 trillion in 2020 to $4.5 trillion in 2022 (17.3% incr).
US saved >$400 billion in 2022 by using generic and biosimilar drugs, https://t.co/Z8kS4elyA3 https://t.co/3LopIiQiqZ
Links:
Dr. John Cush @RheumNow ( View Tweet)
Full read review on the detection & management of #ILD in Autoimmune Dz (AID).
- AID at risk for ILD should be screened with hi-res CT Scan
- ILD should be monitored closely w/ PFTs
- Multidisciplinary Rx includes immunosuppressives & antifibrotics https://t.co/bk7kc5Piyq https://t.co/ktvhS214gS
Dr. John Cush @RheumNow ( View Tweet)
Claims study presented at SASM mtg by HSS orthopedists found among >100k Hip/Knee replacement surgeries, the 19% who used CPAP (OSA) had significantly fewer ER visits and postop complications. https://t.co/kg7oCRndqH https://t.co/WRcxUD3c6V
Dr. John Cush @RheumNow ( View Tweet)
Dr. Lindsey Criswell Elected to National Academy of Medicine. Dr. Criswell is the NIAMS Director and is known for her research in SLE, RA, and Sjogrens. Congrats!! https://t.co/3l4VHqnH2m https://t.co/FDcNVGjw4l
Dr. John Cush @RheumNow ( View Tweet)
Manual labor jobs have more work disability in #PsA. 564 PsA pts, 29% were Blue collar; 71% White Collar. BCol (80% male) had more work disability at baseline (84% vs 28%; p < 0.01). Occupation did not influence DAS28-CRP remission at 1 yr, suggesting Rx response unaffected by… https://t.co/A9E5WZqIwu https://t.co/8PelrtpXco
Dr. John Cush @RheumNow ( View Tweet)
Impact of biosimilars on biologic drug development pipelines. https://t.co/7kc0UDVPTy https://t.co/bPV3wAc2XY
Dr. John Cush @RheumNow ( View Tweet)
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK
Dr. John Cush @RheumNow ( View Tweet)
Alendronate Atypical Fractures Back In Court
Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.… https://t.co/DWXsFyzfWs https://t.co/HhROUArYBE
Dr. John Cush @RheumNow ( View Tweet)
Economic and Mental Health Burden of Rheumatoid Arthritis
A University of Mississippi-led comprehensive study of a disorder that affects 4.27 million Americans nationwide is revealing just how significant its burdens are on patients' financial well-being and quality of life.… https://t.co/UpxHJSG6BL https://t.co/luPp1gjlRA
Dr. John Cush @RheumNow ( View Tweet)
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush @RheumNow ( View Tweet)
Inadequate Zoster Vaccination in Immunocompromised Patients
A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.… https://t.co/EV24CQazex https://t.co/jiTuWQySgs
Dr. John Cush @RheumNow ( View Tweet)
Is EBV relevant? It's certainly been linked to the etiol of SLE, RA, Sjögrens, & MS. Ronbinson et al suggests "EBV infection as a potentiator of autoimmune rheumatic diseases" and if Rx targeting of EBV may work in EBV-associated autoimmune diseases. https://t.co/bi630VvHTx https://t.co/tKYtwePaTu
Dr. John Cush @RheumNow ( View Tweet)
NEJM Review Article on
"Cryoglobulinemia — One Name for Two Diseases "
(sign up for free read)
https://t.co/RFLKBeze3a https://t.co/eA3SLmPMdj
Dr. John Cush @RheumNow ( View Tweet)
EULAR has announced its new, open access journal - EULAR Rheumatology Open (ERO) https://t.co/PWPXZ4H2Ku https://t.co/7kHcUpLFXD
Links:
Dr. John Cush @RheumNow ( View Tweet)
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o
Links:
Dr. John Cush @RheumNow ( View Tweet)
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/j54Vnsl50V https://t.co/jaPbigaqgS
Dr. John Cush @RheumNow ( View Tweet)
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/EwplhAPYJH https://t.co/7Vgn2Rtd4f
Dr. John Cush @RheumNow ( View Tweet)
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX.
Join the Revolution in Rheumatology Education!
https://t.co/ygjZRMVkOZ
Links:
Dr. John Cush @RheumNow ( View Tweet)
Men and Women Process Pain Differently
Men and women experience pain relief differently; a new study may help explain why women have more chronic pain and are less responsive to opioid treatments.
https://t.co/MYWAZnqGmA https://t.co/TxofSlsI4M
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
ANA+ Consult (10.18.2024)-
Dot The I, Cross The T (10.11.2024)
-
Stop Counting Bugs (10.4.2024)
RA Risk Radar: Heart Disease, Infection, and Malignancy Sponsored by AbbVie Medical Affairs
Therapeutic Updates
RA Risk Radar: Heart Disease, Infection, and Malignancy
Sponsored by AbbVie Medical Affairs
Listen as rheumatologists Dr. Jeffery Curtis and Dr. Jon Giles review comorbidities that can occur as a consequence of uncontrolled, or under-controlled, inflammation in rheumatoid arthritis. In this conversation they share their clinical expertise on a range of topics, including risk assessment, risk management, and the importance of disease control.
Read Post
A review of two physician case reports. These cases are patients who presented with severe active manifestations of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Read Post
Poster Hall
